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Abstract
Background: Curcumin, as a pro-apoptotic agent, is extensively studied to inhibit tumor cell growth of various
tumor types. Previous work has demonstrated that curcumin inhibits cancer cell growth by targeting multiple
signaling transduction and cellular processes. However, the role of curcumin in regulating cellular bioenergetic
processes remains largely unknown.
Methods: Western blotting and qRT-PCR were performed to analyze the protein and mRNA level of indicated molecules,
respectively. RTCA, CCK-8 assay, nude mice xenograft assay, and in vivo bioluminescence imaging were used to visualize
the effects of curcmin on gastric cancer cell growth in vitro and in vivo. Seahorse bioenergetics analyzer was used to
investigate the alteration of oxygen consumption and aerobic glycolysis rate.
Results: Curcumin significantly inhibited gastric tumor cell growth, proliferation and colony formation. We further
investigated the role of curcumin in regulating cellular redox homeostasis and demonstrated that curcumin initiated
severe cellular apoptosis via disrupting mitochondrial homeostasis, thereby enhancing cellular oxidative stress in gastric
cancer cells. Furthermore, curcumin dramatically decreased mtDNA content and DNA polymerase γ (POLG) which
contributed to reduced mitochondrial oxygen consumption and aerobic glycolysis. We found that curcumin induced
POLG depletion via ROS generation, and POLG knockdown also reduced oxidative phosphorylation (OXPHOS) activity
and cellular glycolytic rate which was partially rescued by ROS scavenger NAC, indiating POLG plays an important role in
the treatment of gastric cancer. Data in the nude mice model verified that curcumin treatment significantly attenuated
tumor growth in vivo. Finally, POLG was up-regulated in human gastric cancer tissues and primary gastric cancer cell
growth was notably suppressed due to POLG deficiency.
Conclusions: Together, our data suggest a novel mechanism by which curcumin inhibited gastric tumor growth through
excessive ROS generation, resulting in depletion of POLG and mtDNA, and the subsequent disruption of cellular
bioenergetics.
Keywords: Curcumin, Gastric cancer, Cellular bioenergetics, ROS, POLG
* Correspondence: wzmcliangguang@163.com; dry136@163.com
†Equal contributors
6Chemical Biology Research Center, School of Pharmaceutical Sciences,
Wenzhou Medical University, Wenzhou, Zhejiang, China
1Laboratory Animal Centre, Wenzhou Medical University, Wenzhou, Zhejiang,
China
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wang et al. Journal of Experimental & Clinical Cancer Research  (2017) 36:47 
DOI 10.1186/s13046-017-0513-5
Background
Gastric cancer is the fourth most common cancer and
the second most frequent cause of cancer death
worldwide [1]. Advances in diagnostic and therapeutic
approaches have led to excellent expectations for long-
term survival for early gastric cancer, whereas the out-
look for individuals with advanced gastric cancer is still
disappointing [2]. The poor prognosis is frequently ex-
plained by lack of early diagnostic biomarkers and effect-
ive therapeutic treatments [3, 4]. Thus, there is a high
degree of urgency to identify novel more effective thera-
peutic medicine to overcome this challenge.
Curcumin, a diketone compound isolated from the
rhizomes of the plant Curcuma longa commonly known
as “Haldi” in the Indian subcontinent, is one such agent
currently under clinical investigation [5, 6]. The anti-
cancer potential of curcumin has been established
through multiple animal studies. Curcumin is one of the
most successful compounds investigatedin recent years,
and is currently being assessed in human both for
prevention and treatment of cancer [7–13]. Curcumin
exhibits promising pharmacological activities and has
demonstrated beneficial effects in terms of cancer cell
proliferation, growth, survival, apoptosis, migration, in-
vasion, angiogenesis, and metastasis [14–20]. Several re-
ports have demonstrated that curcumin prevents cancer
progression through its anti-inflammatory, antioxidant,
anti-proliferative, and pro-apoptotic activities. Although
the mechanism of action for this dietary agent has yet to
be fully understood, it is believed that curcumin directly
interacts with several proteins, including inflammatory
molecules, cell survival proteins, histone acetyltransfera-
ses(HATs), histone deacetylases (HDAC), protein kinases
and reductases, glyoxalase I (GLOI), proteasome,
sarcoplasmicreticulum Ca2+ ATPase (SERCA), human
immune deficiency virus type 1 (HIV1) integrase and
protease, DNAmethyltransferases 1 (DNMT1), FtsZ
protofilaments, carrier proteins, DNA, RNA, and metal
ions [21–25]. Curcumin also affects several transcription
factors and co-factors, including nuclear factor-kappa-B
(NF-κB) [26–29], activator protein 1 (AP-1) [30],
β-catentin [31, 32], signal transducer and activator of
transcription3 (STAT3) protein [33, 34], and peroxisome
proliferator-activated receptor γ (PPARy) [35, 36]. The
effects of curcumin are mediated, at least inpart, through
intrinsic and extrinsic apoptosis, p53 [37, 38], NF-κB
and NF-κB-regulated gene expression of B cell lymph-
oma 2 (Bcl2) [39–42], cyclin D1 [36], cyclooxygenase-2
(COX-2) [43], matrix metalloproteinase-9 (MMP-9) [44,
45], Akt [46], mitogen activate protein kinase (MAPK)
[47, 48], NF-E2-relatedfactor 2 (Nrf2) [49], and cell–cell
adhesion.
Mitochondria have a major role in cellular bioenerget-
ics in most eukaryotic cells, being responsible for
producing nearly 95% of cellular ATP through mito-
chondrial oxidative phosphorylation as well as the con-
trol of cell death or survival. Mitochondrial-associated
apoptosis is one of the crucial mechanisms of intrinsic
cell apoptosis, disruption of mitochondrial homeostasis
would lead to initiation of this process. Cellular bioener-
getics consists of mitochondrial respiration (OXPHOS)
and aerobic glycolysis which contribute to cell growth
regulation and other cellular functions. Mitochondria
have their own genome known as mtDNA which en-
codes 13 proteins, 2 rRNAs and 22tRNAs [50]. These 13
mitochondrial proteins are the vital subunits of
mitochondrial electron transfer chain complexes in the
maintenance of OXPHOS homeostasis. In tumor cells,
metabolic reprogramming occurs, resulting in the switch
from OXPHOS to aerobic glycolysis to meet the higher
energy demands to support the rapid and uncontrolled
cell growth, a process known as the Warburg effect [51,
52]. Extensive reports support the view that targeting
cellular metabolism could be a promising strategy for
cancer treatment. For example, 2-DG disrupts cellular
glycolysis [53], mitochondrial glutaminase to inhibit
oncogenic transformation [54, 55], AMPK/mTOR axis
to suppress tumor cell growth, and AICAR to directly
activate AMPK to promote cell cycle arrest and cell
apoptosis [56, 57]. Thus, the cellular bioenergetic
process is of importance in regulation of cancer cell
growth and may be a new strategy for cancer treatment.
To date, the potential role of curcumin in regulation
of cellular bioenergetics processes is unclear. In this
study, we investigated the hypothesis that curcumin’s
anti-cancer effect on gastric tumor cell growth is attrib-
uted to disruption of the cellular bioenergetics. Our
findings indicated that curcumin could dramatically
inhibit gastric tumor cell growth and promoted cell
apoptosis. Moreover, we observed that curcumin signifi-
cantly promoted ROS generation and destroyed cellular
bioenergetics, resulting in cancer cell growth inhibition.
We further found that curcumin disrupted cellular bio-
energetics partially due to ROS-mediated POLG deple-
tion, thereby inhibiting mtDNA replication which
further decreased the encoded proteins for energy
supplement. These finding in the gastric tumor cells
were further supported by studies using animal model
and human gastric cancer tissues. In conclusion, we sug-
gest a novel mechanism by which curcumin inhibited
gastric tumor growth through excessive ROS generation
resulting in depletion of POLG and mtDNA, and the
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glucose were purchased from sigma (St. Louis, MO).
Giemsa and crystal violet were purchased from Solarbio
Bioscience & Technology (Shanghai, China). MTT assay
kit, CCK-8, DCFH-DA ROS detection kit, JC-1 mito-
chondrial membrane potential detection kit, horseradish
peroxidase (HRP)-conjugated anti-rabbit, anti-mouse
immunoglobulin G were obtained from Beyotime
(Haimen, China). BCA Protein Assay Kit and Pierce
ECL Western Blotting Substrate were obtained from
Thermo Scientific (Waltham, MA). The monoclonal
antibody against β-actin ((#244586) was from Abmart
(Shanghai, China). POLG (ab128899), COXI (ab14705),
COXII (ab110258), COXIV (ab140643), p-p38T180/
Y182 (ab38238), p38 (ab170099) were purchased from
abcam (HKSP, New Territories, HK). p21 (#10355-1-
AP), ND1 (#19703-1-AP), ND2 (#19704-1-AP) and CytB
(#55090-1-AP) were purchased from Protech Group
(Wuhan, China). p-ERKThr202/Tyr204 (#9101), ERK (#9102),
p-JNKThr183/Tyr185 (#4668), JNK (#9252), phosphor-p53
antibody sampler kit (#9919), Bax (#2774), Bcl-2 (#2870),
p-Aktser473 (#4060) and Akt (#9272) were obtained from
Cell Signaling Technology. Apoptosis detection assay kit
was purchased from BD science.
Cell culture
Human gastric cancer cell lines, SGC-7901 and BGC-
823 were purchased from the Cell Bank of Shanghai In-
stitute of Cell Biology (Shanghai, China).and cultured in
RPMI 1640 (Life Technologies) supplemented with 10%
fetal bovine serum (FBS) (Life Technologies) and antibi-
otics (100 U/ml penicillin and streptomycin) at 37 °C in
a humidified incubator with 5% CO2.
Colony formation assay
Three hundred SGC-7901 and BGC-823 cells/well were
seeded into 6-well plate and cultured at 37 °C with 5%
CO2. Two weeks later, the cells were washed with pre-
warmed PBS for 3 times, fixed with methanol for
20 min, and stained with crystal violet for 15 min. The
cells were next washed with ddH2O to eliminate residual
crystal violet, and colony number was calculated by
Image J software.
Cell proliferation and cell viability assay
For cell proliferation assay, 2 × 103 cells/well were seeded
into five 96-well plates, treated with 10 μg/ml of curcu-
min for 0, 24, 48, 72, or 96 h, and the CCK-8 detection
kit was used to determine the relative cell number. h.
The OD values at 450 nm were read in a plate reader
(Thermo Scientific). Cell viability was assessed using the
MTT assay. Six × 103 cells were plated into a 96-well
plate, treated with curcumin at 0,2.5,5,10,20, or 40 μg/
mL) for 24 h, and assay determined using the MTT kit
according to the manufacture’s protocol. In brief, MTT
reagent (5 μg/mL) was added to the cells and incubated
for 4 h, the crystals produced were dissolved with forma-
zan, and OD values read in plate reader (Thermo
Scientific).
Flow cytometry analysis for apoptosis, ROS determination
and mitochondrial membrane potential
For apoptosis analysis, curcumin (10 μg/mL) pre-treated
SGC-7901 and BGC-823 cells were washed with ice-cold
PBS and collected. Add Annexin V-FITC/PI (BD, San Jose,
CA) mixture followed by incubated at room temperature
for 20 min protected from light. After that, the samples
were subjected to BD AccuriTM C6 flow cytometer (BD,
Franklin Lakes, NJ). Intracellular ROS levels were
measured as described using the fluorescence probe 2′,
7′-dichlorodihydrofluorescein diacetate (DCFH-DA)
according to the manufacturer’s protocol (Beyotime,
Shanghai, China). Cells were collected and washed with
pre-warmed PBS, followed by incubated with DCFH-DA
which dissolved in FBS-free 1640 medium at 37 °C for
20 min. The cells were washed with FBS-free 1640
medium for 2 times and analyzed by FACS. Similarly,
mitochondrial superoxide production was determined
from the curcumin-treated cells by MitoSOX staining dye
according to manufacturer’s instructions, and analyzed by
fluorescence microscopy and FACS; n = 6. For mitochon-
drial membrane potential analysis, curcumin (10 μg/mL
for 4 h) treated SGC and BGC cells were stained with
2.0 μM JC-1 in complete medium, and incubated for
20 min at 37 °C in the dark. Cells were washed with PBS
to remove the excess JC-1 dye, and evaluated by fluores-
cence microscopy.
RNA extraction, quantitative real-time PCR and mtDNA
determination
Total RNA was extracted from SGC-7901 and BGC-
823DNA polymerase γ knockdown cells according to
the manufacturer’s protocol. cDNA was synthesized
using the PrimeScriptTM RT reagent Kit with gDNA
Eraser (Takara, Dalian, China). Quantitative real-time
PCR assays were performed using 2 μl cDNA/20 μl reac-
tion volumes on a CFX connectTM real-time system
(Bio-Rad) using SYBR Green (Bio-Rad) according to the
manufacturer’s protocol. Primer sequences are provided
in the. For cDNA amplification, the thermal cycling was
performed using the following parameters: 95 °C for
10 min, 45 cycles of denaturation at 95 °C for 10 sec and
extension at 60 °C for 30 sec. To quantify the mtDNA
copy number, genomic DNA was isolated and mtDNA
was probed with primers inside ND1 and nuclear DNA
with primer inside β-actin. The threshold cycle number
(CT) was recorded for each reaction. Each sample was
analyzed in triplicate and repeated 3 times. All results
are expressed as means ± SD.
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Western blot analysis
Western blot analysis was performed as described previ-
ously. In brief, equivalent amount of protein extracts
from whole-cell or tissues were separated by SDS-PAGE
followed by electrophoretic transfer onto nitrocellulose
membrane in Tris-glycine buffer. Block the membrane
with 3% non-fat milk in a shaker at room temperature
for 1.5 h followed by incubated with indicated primary
antibodies at 4 °C overnight. After that, recycle the pri-
mary antibodies and wash the membrane 3 × 10 min,
and incubated with corresponding secondary antibodies
at room temperature for 1 h. Finally, membrane were
washed with 1 × TBST for 3 × 10 min and reacted with
ECL reagent according to the manufacturer’s protocol
(Thermo Scientific, Rockford, IL) for 1 min followed by
exposure to X-ray films.
Measurement of oxidative phosphorylation and glycolysis
Real time integrated cellular oxygen consumption rate
(OCR) and extracellular acidification rate (ECAR) were
measured using the Seahorse XF96 Extracellular Flux
Analyser (Seahorse Bioscience, North Billerica, MA,
USA) as previous described. In brief, SGC-7901 or BGC-
823 cells were treated with 10 μg/mL curcumin for 12 h
and 103 cells were plated into the seahorse customized
cell plates. After the probes were calibrated, the OCR
was detected with sequential injection of the following
compounds which regulate mitochondrial respiration:
oligomycin (ATP synthase inhibitor; 1 μM), FCCP (un-
coupler; 1 μM), rotenone (complex I inhibitor; 1 μM),
and antimycin A (complex III inhibitor; 1 μM). Cellular
aerobic glycolysis profile was determined by measuring
ECAR from SGC-7901 or BGC-823 cells treated with
curcumin. Measurements were made after sequential in-
jection of glucose (10 mM), oligomycin (1 μM), or 2-DG
(100 mM); n = 6.F. Basal cellular glycolytic rate in SGC-
7901 and BGC-823 cells treated with or without 10 μg/
mL curcumin. G. Cellular spared glycolytic capacity al-
teration of curcumin treatment in SGC and BGC cells.
Nude mice xenograft assay
BALB/c-nu/nu mice (6–8 wk old, female, ~20 g body-
weight) were purchased from Wenzhou Medical University
laboratory animal center and fed under specific pathogen-
free conditions. All experimental protocols and animal care
were compiled with the Guide for the Care and Use of
Laboratory Animals, Institute of Laboratory Animal
Resources, and were approved by the Institutional Animal
Care and Use Committee of Wenzhou Medical University.
The nude mice were subcutaneously inoculated with 5 × 106
cells of a 0.1 ml BGC cell suspension. And the tumor nod-
ules were allowed to grow to a volume of ~100 mm3 before
initiating treatment. The mice were randomized into three
groups (six mice for each group). The three groups were
intraperitoneally injected with normal saline (control), PBS
and 25 mg/kg of curcumin water suspension, respectively.
The body weight and tumor volume of each mouse were
measured every 2 days over a period of 14 day. The tumor
volume was calculated using the following equation: tumor
volume = length ×width ×width/2. On day 14, the mice
were sacrificed by overdose of sodium pentobarbital, and its
tumor tissues were immediately harvested for further
analysis.
Statistical analysis
All the statistical analysis was performed using SPSS 16.0
(SPSS Standard version 16.0, SPSS Inc., Chicago, IL). Stu-
dent’s t test was used to compare data of different groups.
The data are presented as the mean ± standard deviations
(SD) values obtained from at least three independent experi-
ments. P-values <0.05 was considered statistically significant.
Results
Curcumin inhibits gastric tumor cell growth and
promotes ROS-mediated apoptosis
To investigate the role of curcumin in regulating gastric
tumor cell growth, we determined the effects of curcu-
min concentrations (0-40 μg/ml) on cell viability, and
found a dose-dependent reduction of cell viability (Fig. 1a
and b). Moreover, curcumin treatment (10 μg/ml) de-
creased cell proliferation as monitored for up to 5 days
(Fig. 1b), significantly suppressed tumor cell colony for-
mation in both SGC-7901 and BGC-823 gastric tumor
cells (Fig. 1c). The impact of curcumin in initiating cell
apoptosis was evaluated with the PI/FITC dye to identify
apoptotic versus non-apoptotic cells by flow cytometry
analysis. Results indicated that curcumin treatment
(10 μg/ml) of both gastric cell types induced up to 6-fold
increase over control of apoptotic cells (Fig. 1d). Current
evidence indicated that curcumin likely promoted cell
apoptosis via suppressing the Bcl-2 anti-apoptotic pathway
as well as inactivating ERK/MAPK signaling. Thus, we
asked whether curcumin-mediated gastric tumor cell
apoptosis was also dependent on these pathways. Results
indicated that curcumin reduced ERK activation and de-
creased Bcl-2 level which was accompanied with increased
p53 serine phosphorylation (Fig. 1e). Figure 1f shows
curcumin dramatically disrupted mitochondrial mem-
brane potential, suggesting possible loss of mitochondrial
homeostasis (Fig. 1f). Mitochondria contribute to major
reactive oxygen species (ROS) generation, which is attrib-
uted to the “electron leak” of the electron transport chain
(ETC). Although physiological levels of ROS play an im-
portant role in normal cell proliferation and cellular sig-
naling, the excessive ROS released from mitochondria can
lead to severe oxidative damage and the consequent cell
apoptosis. We observed that curcumin treatment of the
gastric tumor cells resulted in >2-fold increase in the






Fig. 1 Curcumin inhibits gastric tumor cell growth in vitro and promotes apoptosis. a. RTCA was performed to determine the overall cell proliferation curve;
n= 3. b. For cell viability determination, 6 × 103SGC-7901 or BGC-823 cells were seeded into 96-well plates, treated with curcumin at 0,2.5,5,10,20,or 40 μg/mL)
for 24 hand assayed based on MTT (Methods) For determination of proliferation, 2 × 10
3 SGC-7901 or BGC-823 cells were seeded into five 96-well plates,
treated with curcumin (10 μg/mL) for 0-5 days and the relative cell number was assayed using the CCK-8 kit (Method).; n= 5. c. 300 SGC-7901 or BGC-823
cells were cultured in 6-well plates, treated with10 μg/mL curcumin for 5 days, and stained with Giemsa dye for colony formation assessment (Methods);
shown are representative dishes of colonies from the treatment groups, and the quantification of the colony number; n= 3. d. For apoptosis assessment, SGC
and BGC cells were treated with 10 μg/mL curcumin for 24 h, prepared using the Annexin V kit (Methods), and analyzed by flow cytometry; shown are
representative curves and the quantified data for the experimental groups; n= 3. e. Representative Western blot analysis of apoptosis-related proteins and
signaling molecules of cell lysates from SGC or BGC cells treated with 10 μg/Ml curcumin, β-actin used as loading control; f. Mitochondrial membrane
potential was determined from SGC or BGC cells treated with10 μg/mL curcumin and the cells prepared for analysis of the fluorescent membrane potential
indicator, JC-1 (Methods); n= 3. g. Intracellular ROS was detected by using the fluorescent probe, DCFH-DA assay kit (Methods). SGC and BGC cells were
treated with curcumin (10μg/ml) for 12 h and analyzed by FACs; n = 3. h. For mitochondrial superoxide production determination, SGC or BGC cells
were treated with 10 μg/mL curcumin for 12 h,and were prepared for detection of MitoSOX fluorescence (Methods); n = 3. For B-D, F-H, data are
presented as mean ± SD; *p < 0.05, **p < 0.01, ***p < 0.001 compared to control or no DMSO group
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cellular ROS (Fig. 1g). Significantly, the curcumin-induced
increase in ROS content was localized to mitochondria
(Fig. 1h). Collectively, our findings indicated that curcu-
min dramatically promoted cell apoptosis, which was
likely through a mechanism of increased mitochondrial
oxidative stress.
Curcumin suppresses mitochondrial respiration and
aerobic glycolysis
Mitochondria has a major role in cellular bioenergetics
in most eukaryotic cells, being responsible for produ-
cing nearly 95% of cellular ATP through mitochondrial
oxidative phosphorylation, thereby controlling cell
death or survival. We speculated that curcumin would
enhance oxidative damage of mitochondrial integrity,
which could further limit cellular bioenergetics. To test
this hypothesis, we determined the effects of curcumin
on mitochondrial respiration (OXPHOS) and aerobic
glycolysis using the seahorse 96XF Extracellular Flux
Analyser (Methods). As shown in Fig. 2a, curcumin
treatment reduced the intact cell oxygen consumption
rate (OCR), indicating reduced OXPHOSin SGC-7901
and BGC-823 gastric cancer cells. Furthermore, we
assessed specific mitochondrial functions, in particular,
basal respiration, maximal respiration and ATP produc-
tion. As shown in Fig. 2b, curcumin significantly re-
duced basal respiration which represents the basal
mitochondrial OXPHOS activity. Furthermore, in the
presence of the uncoupler agent FCCP, cellular oxygen
consumption was dramatically increased, while this
change was blocked by ETC inhibitors rotenone and
antimycin A, inhibiting electron transfer through
complex I and complex III. As well, curcumin markedly
reduced maximal respiration (Fig. 2c). Integrated mito-
chondrial electron transfer chain, which drives the H+
pump, powers ATP Synthase to catalyze generation of
ATP. In SGC-7901 and BGC-823 cells, we found that
10 μg/mL curcumin significantly reduced ATP produc-
tion (Fig. 2d). These data indicated that curcumin
suppressed mitochondrial respiration, resulting in re-
duced ATP supplement and thereby, restricted cancer
cell growth. Otto Warburg had proposed that cancer is
the result from the regression of cells to a more primi-
tive metabolism, which is exhibited by proliferating
eukaryotic cells, and high aerobic glycolysis may be the
most shared metabolic process in cancer cells. We
therefore, asked whether curcumin also regulates aer-
obic glycolysis to limit tumor growth. We determined
the effects of curcumin on glycolysis using the seahorse
XF96 Extracellular Flux Analyser (Method). Results
indicated that curcumin treatment significantly we de-
creased aerobic glycolysis as measured by extracellular
acidification rate (ECAR) in SGC-7901 and BGC-823
cells (Fig. 2e). To further understand the role of
curcumin in regulating aerobic glycolysis, we analyzed
indices of the basal glycolytic rate and spared glycolytic
capacity. As shown in Fig. 2f, curcumin treatment re-
duced basal glycolytic rate, and together with the ob-
served suppressed mitochondrial respiration, can
dramatically inhibit overall tumor cell growth. More-
over, the spared glycolytic capacity was significantly
blocked within curcumin (Fig. 2g). Taken together, our
findings suggest that curcumin can suppress tumor cell
growth likely by limiting cellular bioenergetics.
Curcumin regulates cellular bioenergetics partially due to
POLG depletion and consequent reduced mtDNA content
Mitochondrial DNA is known to be susceptible to
oxidative damage because of a lack of efficient pro-
tective mechanisms such as histone protection. We
postulated that curcumin-induced elevation of chronic
ROS levels could damage mtDNA, leading to disrup-
tion of mitochondrial respiration. We investigated this
possibility by measuring mtDNA copy number using
real-time PCR and found that curcumin treatment re-
sulted in reduced mtDNA level in SGC-7901 and
BGC-823 cells (Fig. 3a). Moreover, the curcumin-
decreased mtDNA was associated with decreased pro-
tein expression of POLG as well as subunits of the
respiration complex, such as COXI, COXII, COXIV,
CytB (Fig. 3b). POLG is critical for mtDNA replica-
tion, transcription and maintenance of mtDNA integ-
rity. To investigate the effects of POLG in modulating
mitochondrial respiration in gastric cancer biology,
we knockdown POLG using specific target sequences
of siRNA targeted which significantly reduced both
POLG mRNA and protein levels (Fig. 3c). As ex-
pected, POLG knockdown results to reduced expres-
sion of subunits of the mitochondrial respiration
complex (Fig. 3c). Also, the siRNA-induced knock-
down of POLG was associated with reducedmtDNA
copy number (Fig. 3d). Based on these findings, we
asked whether POLG knockdown also lead to a simi-
lar cellular bioenergetics phenotype as that produced
by curcumin. Therefore, we determined alterations of
OCR (assessment of mitochondrial respiration) and
ECAR (assessment of aerobic glycolysis) in gastric
cancer cells with siRNA-induced POLG knockdown
using the Seahorse 96XF Extracellular Flux Analyser.
Results indicated the down-regulated POLG dramatic-
ally decrease overall mitochondrial respiration (Fig. 3e)
and aerobic glycolysis (Fig. 3f ). Additionally, we found
that the downregulated POLG was associated with re-
ductions of basal respiration (Fig. 3g), maximal respir-
ation (Fig. 3h), ATP production (Fig. 3i), basal
glycolytic rate, (Fig. 3j) and glycolytic capacity
(Fig. 3k). We next asked whether excessive ROS gen-
eration induced by curcumin was responsible for the
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POLG depletion. For study, the ROS scavenger, NAC,
was used to block curcumin-induced ROS generation
in the gastric cancer cells. As predicted, NAC effect-
ively rescued the curcumin-induced POLG depletion
as well as the aerobic glycolysis (Fig. 3l-n). Together,
our data indicated that curcumin inhibited cancer cell
growthvia decreasing POLG, thereby reducing mtDNA
content, which further suppressed cellular bioenerget-
ics. These data indicates POLG is significantly in-





Fig. 2 Mitochondrial respiration and aerobic glycolysis are suppressed in response to curcumin. a. Effects of curcumin on real-time mitochondrial oxygen
consumption rate (OCR). SGC-7901 and BGC-823 cells treated with 10 μg/mL curcumin for 12h were evaluated for mitochondrial oxygen consumption using
the Seahorse XF96 analyzer (Methods) after sequential injection (arrows) of the ATP synthase inhibitor oligomycin (1 μM), uncoupler FCCP (1 μM), complex I
inhibitor rotenone (1 μM) and complex III inhibitor antimycin A (1 μM); n= 6. Effects of curcumin (10 μg/ml for 12 h) on b. cellular basal respiration, c. cellular
maximal respiration rates, and d. ATP production of SGC-7901 and BGC-823 cells. e. The cellular aerobic glycolysis was evaluated by measures of the
extracellular acidification rate (ECAR) from SGC-7901 or BGC-823 cells treated with curcumin (10 μg/ml) following sequential injection (arrow) of glucose
(10 mM), oligomycin (1 μM), and 2-DG (100 mM); n= 6. The basal (f) and spared (g) cellular glycolytic rate in SGC-7901 and BGC-823 cells with or without
10 μg/mL curcumin treatment; n= 6. Data are presented as mean ± SD; *p< 0.05, **p< 0.01, ***p< 0.001 compared to control or no DMSO group
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Fig. 3 Curcumin down-regulates mtDNA and POLG to inhibit cellular bioenergetics. a & b Effects of curcumin (10 μg/ml) on mtDNA copy number and
proteins of the respiration complex in SGC-7901 orBGC-823 cells determined by quantitative real-time PCR and Western blot analysis, respectively; shown is
representative blot of the respiration complex proteins with β-actin as loading control; curcumin = cur; c & d Similar Western blot and Q-PCR analyses were
made from SGC-7901 or BGC-823 cells with siRNA-mediated POLG (DNA polymerase γ) knockdown; shown is representative Western blot analysis of
respiration proteins; Effects of POLG knockdown in BGC-823 cells on mitochondrial respiration as determined by real-time mitochondrial oxygen
consumption rate (OCR), n= 6 (e) and aerobic glycolysis as determined by extracellular acidification rate (ECAR), n= 6 (f); arrows indicate sequential injection
of respiration complex modifiers as described in Fig. 2. Effects of POLG siRNA-mediated knock-down in BGC-823 cells on g basal and hmaximal respiration as
determined by mitochondrial OCR, as well as on i ATP production; n= 6. Effects of POLG siRNA-mediated knock-down in BGC-823 cells on j the basal and k
spared glycolytic rates, n= 6. l Shown is representative Western blot analysis of POLG in BGC-823 cells treated N-acetylcysteine (NAC; 10 mM for 4 h) alone or
combined with curcumin (cur; 10 μg/ml for 24 min), β-actin as loading control.m Effects of NAC (10 mM for 4 h) on the curcumin-induced changes in BGC-
823 mitochondrial respiration (OCR), n= 6 and n aerobic glycolysis (ECAR), n= 6; arrows indicate sequential injection of respiration complex modifiers as
described Fig. 2. For a, c-k, m-n, data are shown as mean± SD
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work is needed to uncover the mechanism by which
curcumin downregulates POLG.
Anti-tumor activity of curcumin in vivo
To confirm our data in vivo, we used a xenograft nude
mice model in which BGC cells were subcutaneously
injected (Methods). Curcumin (25 mg/kg) or normal sa-
line was delivered by IP and tumor size evaluated at
14 days. Results indicated that curcumin caused a pro-
gressive decrease in tumor volume as measured for up
to 15 days (Fig. 4a). The body weight was not affected by
curcumin during this treatment period (Fig. 4b), indicat-
ing normal growth condition of the nude mice. As ex-
pected, the curcumin-induced decrease in tumor volume
was also associated with significant decrease in tumor
weight (Fig. 4c). In vivo bioluminescence imaging was
used for further confirmation by visualizing and quantifi-
cation of the effects of curcumin on tumor suppression
(Fig. 4d and e). Evaluation of the tumor histology (H&E)
indicated that the curcumin-treated group presented
with necrosis, resulting in lower cellularity compared to
the mock or vehicle controls (Fig. 4f ). The mtDNA in
tumors from the curcumin-treated group was 50% lower
than that of controls (Fig. 4g), which was associated with
decreased POLG protein expression as well as the indi-
cated proteins we tested (Fig. 4h). Additionally, the
curcumin-treated tumors showed similar changes in ex-
pression of apoptosis-related proteins, signaling, and
proteins of the respiration complex as those in
curcumin-treated gastric cell lines. We next isolated
tumor cells from the xenograft nude mice and knocked
down POLG with siRNA in these tumor cells. Evaluation
of the effects on cellular bioenergetics indicated ECAR
and OCR were predictably suppressed (Fig. 4i and j, re-
spectively). Collectively, our in vivo data validate the
anti-cancer effects and POLG/cellular bioenergetics-
involved mechanism of curcumin.
Expression of POLG and regulation of cellular
bioenergetics in gastric tumor cells from human patients
We further determined POLG expression in gastric tu-
mors isolated from human subjects diagnosed with
gastric cancer, with surrounding normal gastric tissues
as comparison. Results indicated that POLG protein and
mRNA were dramatically upregulated in tumor tissues
compared to normal tissues (Fig. 5a-c). The tumors were
digested for isolation of primary tumor cells for investi-
gation of the effects of curcumin on cellular bioenerget-
ics. We observed that curcumin significantly suppressed
cellular OXPHOS (Fig. 5d) and glycolysis (Fig. 5e). Fur-
thermore, curcumin decreased the indices of OCR, i.e.,
the basal respiration, ATP production and maximal res-
piration (Fig. 5f, g,-h, respectively). And as expected, the
parameters of cellular glycolysis, i.e., basal glycolytic rate
and spare glycolytic rate were both reduced with curcu-
min treatment (Fig. 5i and j, respectively). Furthermore,
we depleted POLG using siRNA in the primary gastric
cancer cells and determined the mitochondrial respir-
ation and aerobic glycolysis. Consistent with data ob-
tained from tumors in the nude mice and the gastric
cancer cell lines, POLG depletion resulted in reduced
respiration (Fig. 5k) and glycolysis (Fig. 5l). Together, the
data obtained from gastric tumors of human subjects
further confirmed that curcumin repressed gastric can-
cer cell bioenergetics.
Discussion
Curcumin is a promising anti-cancer agent in various
types of tumors. Previous evidence indicated that it sup-
presses and reverts carcinogenesis via multifaceted mo-
lecular targets. Several reports have demonstrated that
curcumin inhibits animal and human cancers, suggesting
that it may serve as a chemo-preventive agent. Numer-
ous in vitro and in vivo experimental models have also
revealed that curcumin regulates several molecules in
signal transduction pathways including NF-κB, Akt,
MAPK, p53, Nrf2, Notch-1, JAK/STAT, β-catenin, and
AMPK [26–49]. Modulation of cell signaling pathways
through the pleiotropic effects of curcumin likely acti-
vate cell death signals and induce apoptosis in cancer
cells, thereby inhibiting the progression of disease.
However, the role of curcumin in regulating cellular bio-
energetics remains unknown. Here, we reported the
mechanism by which curcumin regulates mitochondrial
respiration and aerobic glycolysis.
Firstly, we found that curcumin treatment led to rapid
generation of reactive oxidative species (ROS), enhan-
cing cellular oxidative stress, and thereby leading to cell
apoptosis. Faisal Thayyullathil’s work has validated that
in addition to caspase 3 activation, curcumin-induced
rapid ROS generation leads to AIF release, and the acti-
vation of the caspase-independent apoptotic pathway in
L929 cells [58, 59]. As reviewed by Paul T, ROS could
act like a sword in regulating cancer survival and cell
death. Suitable or chronic increased ROS levels can acti-
vate signaling pathways in tumor cells, whereas excessive
or acute production of ROS may disrupt cell homeosta-
sis via exacerbation of the oxidative damage [60]. These
ROS-dependent changes could suppress tumor cell
growth or oncogenic transformation.
Mitochondria are the energy factory in the eukaryotic
cells producing almost 95% ATP to meet the high energy
requirement. In tumor cells, a few reports indicated that
mitochondrial respiration remains high in spite of the
Warburg effect [51, 52]. We found that curcumin dra-
matically reduced OCR. Therefore, we asked why curcu-
min treatment lead to the severe disruption of
mitochondrial OXPHOS process. Based on our data, we







Fig. 4 Curcumin suppresses gastric tumor growth in vivo. BALB/c-nu/nu were injected subcutaneously with 0.1 ml BGC cell suspension to create a
xenograft assay of tumor growth, mock =mock surgery, vehicle = normal saline, curcumin (25 mg/kg), 6 mice/group (Methods); data reported as follows: a.
Images of nude mice with xenograft showing site of graft. Effects of curcumin on tumor growth is presented as tumor volume changes with time (days).
b. Mouse body weight. c. Tumor weight quantification. d & e. Live imaging and quantification of gastric tumor cells. f. Representative H&E stained
histological image of gastric tumor cells. j. mtDNA copy number alteration of tumor tissues. h.Western blot analysis of apoptosis-related proteins, signaling
pathways, and the mitochondrial respiration complex in tumor tissues, β-actin as loading control. The mouse tumors were collected and digested for
isolation of primary tumor cells. The POLG was knockdown using siRNA, and cells evaluated for: i. mitochondrial respiration as determined by real-time
mitochondrial oxygen consumption rate (OCR), n= 6 and j. aerobic glycolysis as determined by extracellular acidification rate (ECAR), n= 6; arrows indicate
sequential injection of respiration complex modifiers as described in Fig. 2 (Methods). For A-C, E, G, I-J, data are shown as mean ± SD, *p< 0.05, **p< 0.01
compared to mock or vehicle control
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proposed that the curcumin-induced production of ROS
may in turn oxidatively modified enzymes and other
proteins of the mitochondrial respiration complex. High
glycolytic activity appears to be common in various
tumor cells, and targeting this pathway could be a prom-
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Fig. 5 POLG expression in gastric tumors of human subjects and effects of curcumin on the cellular bioenergetics. Gastric cancer (C)and surrounding
normal tissues (N) were isolated from human subjects diagnosed with gastric cancer and evaluated for expression of POLG as follows: a & b. Western
blot analysis, β-actin as loading control (n = 4). POLG mRNA expression (n = 4). The gastric tumor tissues samples were digested for isolation of primary
gastric cancer cells for investigation on the effects of curcumin on cellular bioenergetics; d. The overall respiration as measured by OCR (mitochondrial
oxygen consumption rate), n = 6; e. Aerobic glycolysis as measured by ECAR (extracellular acidification rate), n = 6; f. Basal respiration, n = 6; g. Maximal
respiration, n = 6; h. ATP production; n = 6; i. Basal glycolytic rate, n = 6; and j. Spare glycolytic capacity, n = 6. The POLG in the human primary gastric
cancer cells was knockdown using siRNA, and cells evaluated for: k. mitochondrial respiration as determined by real-time mitochondrial oxygen con-
sumption rate (OCR), n = 6 and l. aerobic glycolysis as determined by extracellular acidification rate (ECAR), n = 6; arrows indicate sequential injection of
respiration complex modifiers as described in Fig. 2 (Methods) m. Schematic working model of curcumin which suppresses gastric tumor cell growth
via (i) enhancing excessive ROS generation and p53/p21 activation to initiate apoptosis; and (ii) depleting POLG leading to reduced mtDNA content,
impaired OXPHOS, and limited energy supplement. For B-L, data are shown as mean ± SD
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indicated that curcumin also significantly depressed
tumor aerobic glycolysis (Fig. 2). The suppression of gly-
colysis by curcumin may be related to the acute ROS
generation, resulting in phosphorylation of serine 15 of
the tumor suppressor protein p53. p53 is reported to
play potential roles in modulating cell survival upon
DNA damage or hypoxia, as well as functioning as a
gene transcription factor [61]. It is also known to be im-
portant in several cellular events, such as apoptosis, cell
cycle arrest, autophagy, ROS accumulation and metabol-
ism. Here, we found that curcumin activated p53, with
potential downstream targets that inhibit tumor growth.
Curcumin is reported to increase expression of p53, Bax,
MDM2, Bak, PUMA,Noxa, and Bim [62–65], but down-
regulate anti-apoptotic factors such asBcl-2, and Bcl-XL
[66]. Bensaad and colleagues also reported that p53 may
activate TIGAR (an inhibitor of the fructose-2, 6-
bisphosphate) to negatively regulate glycolysis [67]. Our
results in this study confirmed these previous findings.
Mitochondrial DNA integrity is crucial for mitochon-
drial homeostasis, and EB-mediated mtDNA depletion
lead to severe OXPHOS alteration, resulting in lower
cell growth and higher susceptibility to cell stress. We
found that curcumin significantly inhibited cellular bio-
energetics, which was associated with reduced mtDNA.
We suspect that mtDNA is sensitive to oxidative stress,
and therefore, the elevated ROS in response to curcumin
likely contributed to the reduced mtDNA observed. In
addition, our data showed that POLG, a key enzyme par-
ticipating in mtDNA replication, was dramatically de-
creased with curcumin treatment. Several reports
indicated that POLG plays a critical role in mtDNA
replication as well as DNA damage repair. Our finding
that curcumin reduced expression of this crucial enzyme
suggests that the decreased mtDNA copy number was
likely related to the reduced POLG, leading to the subse-
quent suppression of mitochondrial respiration. More-
over, POLG’s role in tumor cell growth was further
supported by the finding that POLG knockdown
dramatically delayed cancer cell growth and cellular bio-
energetics. As such, the curcumin-induced downregula-
tion of POLG may also inhibited tumor cell growth
through in part by decreasing mtDNA and the conse-
quent cellular bioenergetics. Interestingly, POLG was
overexpressed in gastric cancer tissues from human
subjects, and curcumin inhibited POLG as well as the
cellular bioenergetics from the isolated primary tumor
cells. However, the mechanism by which curcumin
regulates POLG expression level has yet to be defined
Data obtained from the tumors in the xenograft nude
mouse model provide further confirmation thatcurcu-
min effectively suppressed gastric tumor cell growth,
which was accompanied by reduction of mtDNA and
POLG.
Conclusions
In this study, our findings obtained from gastric cancer
cell lines, tumors from xenograft nude mice, and gastric
tumors from human subjects, provide strong evidence
that curcumin inhibits gastric cancer cell growth via re-
ducing POLG-dependentmitochondrial respiration and
cellular aerobic glycolysis. The findings support a novel
anti-cancer mechanism of curcumin and provides POLG
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